当前期刊: Cancer Go to current issue    加入关注   
显示样式:        排序: 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Burden of comorbidities is higher among elderly survivors of oropharyngeal cancer compared with controls
    Cancer (IF 6.102) Pub Date : 2020-01-14
    Elaine O. Bigelow; Amanda L. Blackford; Danielle F. Eytan; David W. Eisele; Carole Fakhry

    The prevalence of survivors of oropharyngeal cancer (OPC) is increasing due to improved survival for individuals with human papillomavirus (HPV)–related disease. Although elderly survivors of OPC are known to have a high burden of comorbidities, to the authors' knowledge it is unknown how this compares with a similar cohort without a history of cancer.

    更新日期:2020-01-14
  • Clustering of cutaneous T‐cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia
    Cancer (IF 6.102) Pub Date : 2020-01-14
    Lindsay Clough; A. Rana Bayakly; Kevin C. Ward; Mohammad K. Khan; Suephy C. Chen; Mary Jo Lechowicz; Christopher R. Flowers; Pamela B. Allen; Jeffrey M. Switchenko

    Cutaneous T‐cell lymphoma (CTCL) is a rare form of non‐Hodgkin lymphoma arising in the skin. Geographic clustering of CTCL has recently been reported, but its association with environmental factors is unknown. Benzene and trichloroethylene (TCE) are environmental toxins with carcinogenic properties. The authors investigated associations between geographic clustering of CTCL incidence in the state of Georgia with benzene and TCE exposure.

    更新日期:2020-01-14
  • Real‐world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer
    Cancer (IF 6.102) Pub Date : 2020-01-14
    Bora Youn; Nikolaos A. Trikalinos; Vincent Mor; Ira B. Wilson; Issa J. Dahabreh

    Limited data exist regarding the characteristics and survival outcomes of older adults with non–small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors in routine oncology practice.

    更新日期:2020-01-14
  • Systemic therapy for elderly patients with non–small cell lung cancer: Where do we stand in 2019?
    Cancer (IF 6.102) Pub Date : 2020-01-14
    Charu Aggarwal; Corey J. Langer

    The 2 articles by Youn et al and Weiss et al in this issue of Cancer confirm that there is no longer room for therapeutic nihilism in the management of older adults with non–small cell lung cancer. Fit elderly patients with preserved Eastern Cooperative Oncology Group performance status should be treated with standard‐of‐care therapies similar to their younger counterparts.

    更新日期:2020-01-14
  • Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy
    Cancer (IF 6.102) Pub Date : 2020-01-14
    Jared M. Weiss; Nathan Pennell; Allison M. Deal; Daniel Morgenzstern; Daniel S. Bradford; Jeffrey Crane; Howard Jack West; Carrie Lee; Chad Pecot; James P. Stevenson; William Irvin; Mark Socinski; Tom Stinchcombe; Liza C. Villaruz; Hyman B. Muss

    The selection of later‐line treatment for older patients with AJCC (version 7) stage IV non–small cell lung cancer (NSCLC) remains controversial. Nanoparticle albumin–bound (nab)‐paclitaxel is approved with carboplatin for the first‐line treatment of patients with NSCLC and subgroup analysis of phase 3 data has suggested superior survival in older patients.

    更新日期:2020-01-14
  • Short‐term mortality risks among patients with oropharynx cancer by human papillomavirus status
    Cancer (IF 6.102) Pub Date : 2020-01-13
    Zoe H. Fullerton; Santino S. Butler; Brandon A. Mahal; Vinayak Muralidhar; Jonathan D. Schoenfeld; Roy B. Tishler; Danielle N. Margalit

    There is substantial variation in head and neck cancer (HNC) mortality and competing mortality among patients with HNC. In this study, the authors characterize the causes and risks of short‐term mortality among patients with oropharynx cancer (OPC) and how these risks differ by human papillomavirus (HPV) status.

    更新日期:2020-01-13
  • Clinically ascertained health outcomes, quality of life, and social attainment among adult survivors of neuroblastoma: A report from the St. Jude Lifetime Cohort
    Cancer (IF 6.102) Pub Date : 2020-01-10
    Carmen L. Wilson; Tara M. Brinkman; Cathleen Cook; Sujuan Huang; Geehong Hyun; Daniel M. Green; Wayne L. Furman; Nickhill Bhakta; Matthew J. Ehrhardt; Matthew J. Krasin; Leslie L. Robison; Kirsten K. Ness; Melissa M. Hudson

    The objective of this study was to characterize chronic disease, health‐related quality of life (HRQOL), emotional distress, and social attainment among long‐term survivors of neuroblastoma.

    更新日期:2020-01-11
  • Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events
    Cancer (IF 6.102) Pub Date : 2020-01-08
    Dawn L. Hershman; Melissa K. Accordino; Sherry Shen; Donna Buono; Katherine D. Crew; Kevin Kalinsky; Meghna S. Trivedi; Chin Hur; Jianhua Hu; Joseph M. Unger; Jason D. Wright

    Cardiovascular disease (CVD) is the leading cause of death among patients with early‐stage breast cancer (BC), but adherence to cardiovascular disease risk factor (CVD‐RF) medications is reported to be poor in BC survivors. The objective of the current study was to determine the association between nonadherence to CVD‐RF medications and cardiovascular events in BC survivors.

    更新日期:2020-01-08
  • Neurocognitive and psychosocial outcomes in adult survivors of childhood soft‐tissue sarcoma: A report from the St. Jude Lifetime Cohort
    Cancer (IF 6.102) Pub Date : 2020-01-08
    Ingrid Tonning Olsson; Tara M. Brinkman; Mingjuan Wang; Matthew J. Ehrhardt; Pia Banerjee; Daniel A. Mulrooney; I‐Chan Huang; Kirsten K. Ness; Michael W. Bishop; Deokumar Srivastava; Leslie L. Robison; Melissa M. Hudson; Kevin R. Krull

    To the authors' knowledge, few studies to date have examined long‐term neurocognitive outcomes in survivors of childhood soft‐tissue sarcoma.

    更新日期:2020-01-08
  • Fear of cancer recurrence promotes cancer screening behaviors among family caregivers of cancer survivors
    Cancer (IF 6.102) Pub Date : 2020-01-08
    Emi Takeuchi; Youngmee Kim; Kelly M. Shaffer; Rachel S. Cannady; Charles S. Carver

    Fear of cancer recurrence (FCR) has been associated with cancer screening behaviors among cancer survivors, but to the authors' knowledge, the question of whether the same is true for caregivers is unknown. The current study investigated the extent to which FCR among caregivers predicted their cancer screening behaviors years after their relatives' cancer diagnosis.

    更新日期:2020-01-08
  • Screening young adult cancer survivors with the PROMIS Depression Short Form (PROMIS‐D‐SF): Comparison with a structured clinical diagnostic interview
    Cancer (IF 6.102) Pub Date : 2020-01-08
    Christopher J. Recklitis; Jaime E. Blackmon; Grace Chang

    The current study was conducted to evaluate the Patient‐Reported Outcomes Measurement Information System Depression Short Form (PROMIS‐D‐SF) as a screening measure for young adult cancer survivors (YACS) compared with a structured diagnostic interview.

    更新日期:2020-01-08
  • Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis
    Cancer (IF 6.102) Pub Date : 2020-01-08
    Rajshekhar Chakraborty; Irbaz Bin Riaz; Saad Ullah Malik; Naimisha Marneni; Alex Mejia Garcia; Faiz Anwer; Alok A. Khorana; S. Vincent Rajkumar; Shaji Kumar; M. Hassan Murad; Zhen Wang; Safi U. Khan; Navneet S. Majhail

    Thromboprophylaxis is routinely used with lenalidomide‐based regimens in multiple myeloma because of a substantial risk of venous thromboembolism (VTE). However, little is known about the incidence of VTE with contemporary lenalidomide‐based regimens. The objective of the current study was to estimate the incidence of VTE despite thromboprophylaxis with currently used lenalidomide‐based regimens in patients with myeloma.

    更新日期:2020-01-08
  • Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics
    Cancer (IF 6.102) Pub Date : 2020-01-08
    Cameron M. Phillips; Ambica Parmar; Helen Guo; Deborah Schwartz; Wanrudee Isaranuwatchai; Jaclyn Beca; Wei Dai; Jessica Arias; Scott Gavura; Kelvin K. W. Chan

    Although increasing evidence has suggested that an efficacy‐effectiveness gap exists between clinical trial (CT) and real‐world evidence (RWE), to the authors' knowledge, the magnitude of this difference remains undercharacterized. The objective of the current study was to quantify the magnitude of survival and toxicity differences between CT and RWE for contemporary cancer systemic therapies.

    更新日期:2020-01-08
  • Development of the Functional Assessment of Cancer Therapy–Immune Checkpoint Modulator (FACT‐ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs
    Cancer (IF 6.102) Pub Date : 2020-01-08
    Aaron R. Hansen; Kari Ala‐Leppilampi; Chris McKillop; Lillian L. Siu; Philippe L. Bedard; Albiruni R. Abdul Razak; Anna Spreafico; Srikala S. Sridhar; Natasha Leighl; Marcus O. Butler; David Hogg; Adrian Sacher; Amit M. Oza; Rany Al‐Agha; Catherine Maurice; Christopher T. Chan; Shane Shapera; Jordan J. Feld; Rosane Nisenbaum; Kimberly Webster; David Cella; Janet Parsons

    Patients with cancer who are treated with immune checkpoint modulators (ICMs) have their health‐related quality of life (HRQOL) measured using general patient‐reported outcome (PRO) tools. To the authors' knowledge, no instrument has been developed to date specifically for patients treated with ICMs. The objective of the current study was to develop a toxicity subscale PRO instrument for patients treated with ICMs to assess HRQOL.

    更新日期:2020-01-08
  • An invitation for optimal inclusivity: Investing in communities to advance equity in biomedical research and cancer care
    Cancer (IF 6.102) Pub Date : 2020-01-07
    Cathy D. Meade; Clement K. Gwede

    Strategic efforts to optimize diversity and inclusivity in biomedical research and clinical trials are essential to ensure the greatest benefit for demographically diverse populations and communities. In this editorial, the authors call for researchers to have a proactive “inclusivity mindset” when planning and conducting research to achieve health equity.

    更新日期:2020-01-07
  • Factors associated with biomedical research participation within community‐based samples across 3 National Cancer Institute–designated cancer centers
    Cancer (IF 6.102) Pub Date : 2020-01-07
    Nadine J. Barrett; Elisa M. Rodriguez; Ronaldo Iachan; Terry Hyslop; Kearston L. Ingraham; Gem M. Le; Kelly Martin; Rodney C. Haring; Natalie A. Rivadeneira; Deborah O. Erwin; Laura J. Fish; Deidre Middleton; Robert A. Hiatt; Steven R. Patierno; Urmimala Sarkar; Elizabeth A. Gage‐Bouchard

    Engaging diverse populations in biomedical research, including biospecimen donation, remains a national challenge. This study examined factors associated with an invitation to participate in biomedical research, intent to participate in biomedical research in the future, and participation in biomedical research and biospecimen donation among a diverse, multilingual, community‐based sample across 3 distinct geographic areas.

    更新日期:2020-01-07
  • Circulating epigenetic biomarkers for detection of recurrent colorectal cancer
    Cancer (IF 6.102) Pub Date : 2020-01-07
    Erin L. Symonds; Susanne K. Pedersen; David Murray; Susan E. Byrne; Amitesh Roy; Christos Karapetis; Paul Hollington; Philippa Rabbitt; Frederick S. Jones; Lawrence LaPointe; Eva Segelov; Graeme P. Young

    The sensitive detection of recurrent colorectal cancer (CRC) by the measurement of circulating tumor DNA (ctDNA) might improve the chance of a cure. This study compared a quantitative methylated ctDNA test with carcinoembryonic antigen (CEA) in the setting of surveillance for recurrence.

    更新日期:2020-01-07
  • Breast cancer screening disparities between women with and without disabilities: A national database study in South Korea
    Cancer (IF 6.102) Pub Date : 2020-01-06
    Dong Wook Shin; Jonghan Yu; Juhee Cho; Se Kyung Lee; Jin Hyung Jung; Kyungdo Han; So Young Kim; Jung Eun Yoo; Kyoung Eun Yeob; Yeon Yong Kim; Jong Heon Park; Jong Hyock Park; Ichiro Kawachi

    Health disparities among individuals with disabilities remain underrecognized. The objective of the current study was to investigate: 1) whether disparities exist in breast cancer screening rates among women with disabilities compared with women without disabilities; 2) whether breast cancer screening rates vary according to the type and severity of disabilities; and 3) trends in breast cancer screening disparities according to disability status over time.

    更新日期:2020-01-06
  • Genomic and clinical characterization of stromal infiltration markers in prostate cancer
    Cancer (IF 6.102) Pub Date : 2020-01-06
    Brandon A. Mahal; Mohammed Alshalalfa; Shuang G. Zhao; Himisha Beltran; William S. Chen; Fallon Chipidza; Elai Davicioni; R. Jeffrey Karnes; Sheng‐Yu Ku; Tamara L. Lotan; Vinayak Muralidhar; Timothy R. Rebbeck; Edward M. Schaeffer; Daniel E. Spratt; Felix Y. Feng; Paul L. Nguyen

    The progression of prostate cancer is a complex, multistep process that involves molecular alterations in cells of the tumor and the microenvironment, with associated interactions between the stroma and epithelium. Genomic expression analyses of stromal infiltration markers were performed to determine the significance thereof in prostate cancer.

    更新日期:2020-01-06
  • Age dependence of modern clinical risk groups for localized prostate cancer—A population‐based study
    Cancer (IF 6.102) Pub Date : 2020-01-03
    Minh‐Phuong Huynh‐Le; Tor Åge Myklebust; Christine H. Feng; Roshan Karunamuni; Tom Børge Johannesen; Anders M. Dale; Ole A. Andreassen; Tyler M. Seibert

    Optimal prostate cancer (PCa) screening strategies will focus on men likely to have potentially lethal disease. Age‐specific incidence rates (ASIRs) by modern clinical risk groups could inform risk stratification efforts for screening.

    更新日期:2020-01-04
  • The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study
    Cancer (IF 6.102) Pub Date : 2020-01-03
    Amber Khan; Nidha Mubdi; Amy Budnick; Darren R. Feldman; Sharon W. Williams; Seema Patel; Emily S. Tonorezos

    Hearing loss is a prevalent late effect among cancer survivors. Despite the significant social costs, there is a noted delay in seeking care and to the authors' knowledge there are limited data regarding the lived experiences of cancer survivors with hearing loss. The objective of the current study was to explore the lived experience of hearing loss in survivors of childhood and young adult cancers to guide survivorship care.

    更新日期:2020-01-04
  • Multimodal psychosocial intervention for family caregivers of patients undergoing hematopoietic stem cell transplantation: A randomized clinical trial
    Cancer (IF 6.102) Pub Date : 2020-01-03
    Areej El‐Jawahri; Jamie M. Jacobs; Ashley M. Nelson; Lara Traeger; Joseph A. Greer; Showly Nicholson; Lauren P. Waldman; Alyssa L. Fenech; Annemarie D. Jagielo; Jennifer D’Alotto; Nora Horick; Thomas Spitzer; Zachariah DeFilipp; Yi‐Bin A. Chen; Jennifer S. Temel

    Caregivers of patients undergoing hematopoietic stem cell transplantation (HCT) experience an immense caregiving burden before, during, and after HCT.

    更新日期:2020-01-04
  • Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma
    Cancer (IF 6.102) Pub Date : 2019-12-30
    Jamie R. Oliver; Seth M. Lieberman; Moses M. Tam; Cheng Z. Liu; Zujun Li; Kenneth S. Hu; Luc G. T. Morris; Babak Givi

    To the authors' knowledge, the question of whether human papillomavirus (HPV) infection is associated with outcomes in patients with sinonasal squamous cell carcinoma (SNSCC) is not well studied at this time. In the current study, the authors investigated patterns of HPV testing and its association with survival in patients with SNSCC using the National Cancer Data Base.

    更新日期:2019-12-30
  • Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
    Cancer (IF 6.102) Pub Date : 2019-12-27
    Maria M. Rubinstein; David M. Hyman; Imogen Caird; Helen Won; Krysten Soldan; Kenneth Seier; Alexia Iasonos; William P. Tew; Roisin E. O’Cearbhaill; Rachel N. Grisham; Martee L. Hensley; Tiffany Troso‐Sandoval; Paul Sabbatini; Joyce Guillen; S. Duygu Selcuklu; Catherine Zimel; Jean Torrisi; Carol Aghajanian; Vicky Makker

    PI3K pathway activation is common in endometrial cancer. We evaluated the safety and efficacy of the dual PI3K/mTOR inhibitor, LY3023414, in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.

    更新日期:2019-12-27
  • 2b or not 2b? Shoulder function after level 2b neck dissection: A double‐blind randomized controlled clinical trial
    Cancer (IF 6.102) Pub Date : 2019-12-24
    Peter T. Dziegielewski; Margaret L. McNeely; Nigel Ashworth; Daniel A. O’Connell; Brittany Barber; Kerry S. Courneya; Brock J. Debenham; Hadi Seikaly

    Selective neck dissection (SND) is a mainstay of head and neck cancer treatment. A common sequela is shoulder syndrome from spinal accessory nerve (SAN) trauma. Extensive dissection in neck levels 2 and 5 leads to SAN dysfunction. However, it is not known whether limited level 2 dissection reduces SAN injury. The purpose of this double‐blind randomized controlled trial was to determine whether omitting level 2b dissection would improve shoulder‐related quality of life and function.

    更新日期:2019-12-25
  • Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention guidelines and colorectal cancer incidence among African Americans and whites: The Atherosclerosis Risk in Communities study
    Cancer (IF 6.102) Pub Date : 2019-12-24
    Guillaume Onyeaghala; Anna K. Lintelmann; Corrine E. Joshu; Pamela L. Lutsey; Aaron R. Folsom; Kimberly Robien; Elizabeth A. Platz; Anna E. Prizment

    Adherence to the World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) cancer prevention recommendations is associated with colorectal cancer (CRC) risk in whites, but only 1 previous study has reported on this link in African Americans. This study assessed the association between the 2018 WCRF/AICR guidelines and CRC incidence in African Americans (26.5%) and whites (73.5%) in the Atherosclerosis Risk in Communities prospective cohort (n = 13,822).

    更新日期:2019-12-25
  • Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation
    Cancer (IF 6.102) Pub Date : 2019-12-24
    Armin Rashidi; Thomas Kaiser; Carolyn Graiziger; Shernan G. Holtan; Tauseef Ur Rehman; Daniel J. Weisdorf; Gary M. Dunny; Alexander Khoruts; Christopher Staley

    In the field of malignant hematology, most microbiome studies have focused on recipients of allogeneic hematopoietic cell transplantation (allo‐HCT). As a result, this population has remained the primary target for novel microbiota therapeutics. Because the types of insults to the microbiome are similar during hematopoietic cell transplantation and intensive antileukemia therapy, this study evaluated whether the dysbiosis states are similar in the 2 settings.

    更新日期:2019-12-25
  • Geographically distributed data should be analyzed with spatial epidemiologic methods
    Cancer (IF 6.102) Pub Date : 2019-12-24
    Elizabeth Garrett‐Mayer

    Comparisons of crude incidence and mortality rates for acute myeloid leukemia cannot be used to determine whether cancer clusters exist. Geographic data should be analyzed via spatial modeling with appropriate adjustments for known prognostic factors.

    更新日期:2019-12-25
  • Considering adjuvant therapy for stage II melanoma
    Cancer (IF 6.102) Pub Date : 2019-12-23
    Andrew S. Poklepovic; Jason J. Luke

    Melanoma is among the few cancers that demonstrate an increasing incidence over time. Simultaneously, this trend has been marked by an epidemiologic shift to earlier stage at diagnosis. Before 2011, treatment options were limited for patients with metastatic disease, and the median overall survival was less than 1 year. Since then, the field of melanoma therapeutics has undergone major changes. The use of anti–CTLA‐4 and anti‐PD1 immune checkpoint inhibitors and combination BRAF/MEK inhibitors for patients with BRAF V600 mutations has significantly extended survival and allowed some patients to remain in durable disease remission off therapy. It has now been confirmed that these classes of agents have a benefit for patients with stage III melanoma after surgical resection, and anti‐PD1 and BRAF/MEK inhibitors are standards of care in this setting. Some patients with stage II disease (lymph node‐negative; American Joint Committee on Cancer stage IIB and IIC) have worse melanoma‐specific survival relative to some patients with stage III disease. Given these results, expanding the population of patients who are considered for adjuvant therapy to include those with stage II melanoma has become a priority, and randomized phase 3 clinical trials are underway. Moving into the future, the validation of patient risk‐stratification and treatment‐benefit prediction models will be important to improve the number needed to treat and limit exposure to toxicity in the large population of patients with early stage melanoma.

    更新日期:2019-12-25
  • Systematic review of barriers and facilitators to clinical trial enrollment among adolescents and young adults with cancer: Identifying opportunities for intervention
    Cancer (IF 6.102) Pub Date : 2019-12-23
    Elizabeth J. Siembida; Holli A. Loomans‐Kropp; Neha Trivedi; Ann O’Mara; Lillian Sung; Irene Tami‐Maury; David R. Freyer; Michael Roth

    Adolescents and young adults (AYAs) are underrepresented in cancer clinical trials (CCTs). Limited trial enrollment slows progress in improving survival rates and prevents the collection of valuable biospecimens. A systematic literature review was conducted to assess barriers and facilitators to AYA enrollment in CCTs and to identify opportunities to improve enrollment. The PubMed MEDLINE, Web of Science, Scopus, and PsycINFO databases were searched to identify studies relevant to AYA CCT enrollment. Eligibility criteria included the qualitative and/or quantitative evaluation of barriers and facilitators to AYA enrollment. One hundred fifty‐five unique publications were identified; 13 were included in the final analysis. Barriers to AYA enrollment in CCTs included a lack of existing trials applicable to the patient population, limited access to available CCTs, and a lack of physician awareness of relevant trials. Facilitators of enrollment included optimizing the research infrastructure, improving the awareness of available CCTs among providers, and enhancing communication about CCTs between providers and patients. In conclusion, the limited available research reports institution‐ and patient‐level barriers and facilitators to AYA CCT enrollment. Because of persistent disparities in AYA enrollment, there is an urgent need to further identify the barriers and facilitators to AYA CCT enrollment to determine actionable areas for intervention.

    更新日期:2019-12-25
  • The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics
    Cancer (IF 6.102) Pub Date : 2019-12-23
    Shengjie Zhang; Ruth O’Regan; Wei Xu

    Transcriptional dysregulation induced by disease‐defining genetic alterations of proteins in transcriptional machinery is a key feature of cancers. Mediator complex subunit 12 (MED12) is the central architectural subunit in the kinase module of Mediator, a large transcriptional regulatory complex that controls essential steps of transcription. Emerging evidence links deregulated MED12 to human cancers. MED12 is frequently mutated in benign tumors and cancers. Although the missense mutations of MED12 in benign tumors disrupt the kinase activity of Mediator, MED12 mutations in cancers could eliminate the interaction between Mediator complex and RNA polymerase II, leading to severe transcriptional misregulation. Aberrant expression of MED12 is associated with the prognosis of various types of human cancers. Loss of MED12 function has been associated with the development of resistance to chemotherapeutics. Moreover, MED12 is modified by posttranscriptional regulations. Arginine methylation of MED12 has been shown to regulate MED12‐mediated transcriptional regulation and response to chemotherapeutics in human cancer cell lines. In this mini‐review, the authors provide an overview of the roles of MED12 in the development of benign and malignant tumors as well as its roles in chemoresistance. The studies of MED12 exemplify that aberrant transcriptional programming is a therapeutic vulnerability for certain types of cancer.

    更新日期:2019-12-25
  • A single‐institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer
    Cancer (IF 6.102) Pub Date : 2019-12-23
    Gregory M. Hermann; Austin J. Iovoli; Alexis J. Platek; Chong Wang; Austin Miller; Kristopher Attwood; Daniel J. Bourgeois; Anurag K. Singh

    The objective of the current study was to compare the safety and efficacy between 2 analgesic regimens for patients with head and neck cancer (HNC) undergoing definitive chemoradiation (CRT).

    更新日期:2019-12-25
  • Disparities in risk perception of thyroid cancer recurrence and death
    Cancer (IF 6.102) Pub Date : 2019-12-23
    Debbie W. Chen; David Reyes‐Gastelum; Lauren P. Wallner; Maria Papaleontiou; Ann S. Hamilton; Kevin C. Ward; Sarah T. Hawley; Brian J. Zikmund‐Fisher; Megan R. Haymart

    To the authors' knowledge, studies regarding risk perception among survivors of thyroid cancer are scarce.

    更新日期:2019-12-25
  • Value assessment of oncology drugs using a weighted criterion‐based approach
    Cancer (IF 6.102) Pub Date : 2019-12-20
    Doreen A. Ezeife; Francois Dionne; Aline Fusco Fares; Ellen Laura Rose Cusano; Rouhi Fazelzad; Wenzie Ng; Don Husereau; Farzad Ali; Christina Sit; Barry Stein; Jennifer H. Law; Lisa Le; Peter Michael Ellis; Scott Berry; Stuart Peacock; Craig Mitton; Craig C. Earle; Kelvin K. W. Chan; Natasha B. Leighl

    Globally, the rising cost of anticancer therapy has motivated efforts to quantify the overall value of new cancer treatments. Multicriteria decision analysis offers a novel approach to incorporate multiple criteria and perspectives into value assessment.

    更新日期:2019-12-21
  • Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study
    Cancer (IF 6.102) Pub Date : 2019-12-20
    Jeanne S. Mandelblatt; Wanting Zhai; Jaeil Ahn; Brent J. Small; Tim A. Ahles; Judith E. Carroll; Neelima Denduluri; Asma Dilawari; Martine Extermann; Deena Graham; Arti Hurria; Claudine Isaacs; Paul B. Jacobsen; Heather S. L. Jim; George Luta; Brenna C. McDonald; Sunita K. Patel; James C. Root; Andrew J. Saykin; Danielle B. Tometich; Xingtao Zhou; Harvey J. Cohen

    Little is known about longitudinal symptom burden, its consequences for well‐being, and whether lifestyle moderates the burden in older survivors.

    更新日期:2019-12-20
  • Potentially burdensome end‐of‐life transitions among nursing home residents with poor‐prognosis cancer
    Cancer (IF 6.102) Pub Date : 2019-12-20
    Daniel E. Lage; Clark DuMontier; Yoojin Lee; Ryan D. Nipp; Susan L. Mitchell; Jennifer S. Temel; Areej El‐Jawahri; Sarah D. Berry

    This study examined factors associated with potentially burdensome end‐of‐life (EOL) transitions between care settings among older adults with advanced cancer in nursing homes (NHs).

    更新日期:2019-12-20
  • A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia
    Cancer (IF 6.102) Pub Date : 2019-12-20
    Rupa Narayan; Traci M. Blonquist; Ashkan Emadi; Robert P. Hasserjian; Meghan Burke; Christopher Lescinskas; Donna S. Neuberg; Andrew M. Brunner; Gabriela Hobbs; Hanno Hock; Steven L. McAfee; Yi‐Bin Chen; Eyal Attar; Timothy A. Graubert; Christina Bertoli; Jenna A. Moran; Meghan K. Bergeron; Julia E. Foster; Aura Y. Ramos; Tina T. Som; Megan K. Vartanian; Jennifer L. Story; Kristin McGregor; Molly Macrae; Tanya Behnan; Margaret C. Wey; Jessica Rae; Frederic I. Preffer; Patricia Lesho; Vu H. Duong; Mason L. Mann; Karen K. Ballen; Christine Connolly; Philip C. Amrein; Amir T. Fathi

    Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high interest. Brentuximab vedotin (BV) is an antibody‐drug conjugate that is specific for human CD30. In this phase 1 dose escalation study, the authors evaluated the safety of BV combined with mitoxantrone, etoposide, and cytarabine (MEC) re‐induction chemotherapy for patients with CD30‐expressing R/R AML.

    更新日期:2019-12-20
  • Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
    Cancer (IF 6.102) Pub Date : 2019-12-20
    Francesca Palandri; Massimo Breccia; Massimiliano Bonifacio; Nicola Polverelli; Elena M. Elli; Giulia Benevolo; Mario Tiribelli; Elisabetta Abruzzese; Alessandra Iurlo; Florian H. Heidel; Micaela Bergamaschi; Alessia Tieghi; Monica Crugnola; Francesco Cavazzini; Gianni Binotto; Alessandro Isidori; Nicola Sgherza; Costanza Bosi; Bruno Martino; Roberto Latagliata; Giuseppe Auteri; Luigi Scaffidi; Davide Griguolo; Malgorzata Trawinska; Daniele Cattaneo; Lucia Catani; Mauro Krampera; Roberto M. Lemoli; Antonio Cuneo; Gianpietro Semenzato; Robin Foà; Francesco Di Raimondo; Daniela Bartoletti; Michele Cavo; Giuseppe A. Palumbo; Nicola Vianelli

    After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with myelofibrosis and whether reasons for drug discontinuation, disease phase at discontinuation, and salvage therapies may influence the outcome.

    更新日期:2019-12-20
  • Nodal positivity decreases with age in women with early‐stage, hormone receptor–positive breast cancer
    Cancer (IF 6.102) Pub Date : 2019-12-20
    Stephanie M. Downs‐Canner; Charles E. Gaber; Raphael J. Louie; Paula D. Strassle; Kristalyn K. Gallagher; Hyman B. Muss; David W. Ollila

    Despite data demonstrating the safety of omitting axillary surgery in older women with early‐stage breast cancer, the incidence of axillary surgery remains high. It was hypothesized that the prevalence of nodal positivity would decrease with advancing age.

    更新日期:2019-12-20
  • Colorectal cancer screening patterns after the American Cancer Society’s recommendation to initiate screening at age 45 years
    Cancer (IF 6.102) Pub Date : 2019-12-18
    Stacey A. Fedewa; Rebecca L. Siegel; Ann Goding Sauer; Priti Bandi; Ahmedin Jemal

    In May 2018, the American Cancer Society updated its colorectal cancer (CRC) screening guidelines, lowering the age to initiate screening among average‐risk individuals from 50 years to 45 years because of increasing risk in younger generations and a favorable benefit‐to‐harm ratio. Herein, the authors report that past‐year CRC testing among individuals aged 45 to 49 years more than doubled during 2018 in concert with the Society lowering the recommended age for screening.

    更新日期:2019-12-19
  • Efficacy and Safety of Tailored and Dose‐Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2‐Positive Breast Cancer: Results From the Phase 3 PANTHER Trial
    Cancer (IF 6.102) Pub Date : 2019-12-18
    Antroula Papakonstantinou; Alexios Matikas; Nils Olof Bengtsson; Per Malmström; Elham Hedayati; Guenther Steger; Michael Untch; Laila Hübbert; Hemming Johansson; Mats Hellström; Michael Gnant; Sibylle Loibl; Richard Greil; Volker Moebus; Theodoros Foukakis; Jonas Bergh

    Dose‐dense (DD) adjuvant chemotherapy improves outcomes in early breast cancer (BC). However, there are no phase 3 randomized data to inform on its combination with trastuzumab for patients with human epidermal growth factor receptor 2 (HER2)–positive disease.

    更新日期:2019-12-19
  • New‐onset persistent opioid use following breast cancer treatment in older adult women
    Cancer (IF 6.102) Pub Date : 2019-12-17
    Andrew W. Roberts; Nicole Fergestrom; Joan M. Neuner; Aaron N. Winn

    Patients with cancer‐related pain are underrepresented in the opioid literature despite high opioid exposure and numerous risk factors for adverse opioid outcomes, including unnecessary persistent opioid use. The objective of this study was to determine the extent, historical trends, and predictors of new‐onset persistent opioid use among older adult women after active breast cancer treatment.

    更新日期:2019-12-18
  • Restoring balance to cancer pain management
    Cancer (IF 6.102) Pub Date : 2019-12-17
    James F. Cleary

    Pain is one of the most common symptoms of cancer and is often thought to be the most feared by patients with advanced disease. Cancer pain management, an often neglected component of oncological care, has been closely linked with the development of the modern hospice movement, with its focus on research and education, and the parallel development of palliative care.

    更新日期:2019-12-18
  • Causes of death after breast cancer diagnosis: A US population‐based analysis
    Cancer (IF 6.102) Pub Date : 2019-12-16
    Ahmed M. Afifi; Anas M. Saad; Muneer J. Al‐Husseini; Ahmed Osama Elmehrath; Donald W. Northfelt; Mohamad Bassam Sonbol

    The focus on noncancer causes of death in patients with breast cancer (BC) remains superficial. The objective of the current study was to assess and quantify causes of death after BC diagnosis.

    更新日期:2019-12-17
  • Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with checkpoint inhibitors
    Cancer (IF 6.102) Pub Date : 2019-12-12
    Ali Raza Khaki; Ang Li; Leonidas N. Diamantopoulos; Mehmet A. Bilen; Victor Santos; John Esther; Rafael Morales‐Barrera; Michael Devitt; Ariel Nelson; Christopher J. Hoimes; Evan Shreck; Hussein Assi; Benjamin A. Gartrell; Alex Sankin; Alejo Rodriguez‐Vida; Mark Lythgoe; David J. Pinato; Alexandra Drakaki; Monika Joshi; Pedro Isaacsson Velho; Noah Hahn; Sandy Liu; Lucia Alonso Buznego; Ignacio Duran; Marcus Moses; Jayanshu Jain; Jure Murgic; Praneeth Baratam; Pedro Barata; Abhishek Tripathi; Yousef Zakharia; Matthew D. Galsky; Guru Sonpavde; Evan Y. Yu; Veena Shankaran; Gary H. Lyman; Petros Grivas

    Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with a poor PS remains unknown. It was hypothesized that a poor Eastern Cooperative Oncology Group (ECOG) PS (≥2 vs 0‐1) would correlate with shorter overall survival (OS) in patients receiving ICIs.

    更新日期:2019-12-13
  • Efficacy and safety of trabectedin for patients with unresectable and relapsed soft‐tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study
    Cancer (IF 6.102) Pub Date : 2019-12-11
    Hiroshi Kobayashi, Shintaro Iwata, Toru Wakamatsu, Keiko Hayakawa, Tsukasa Yonemoto, Junji Wasa, Hiroyuki Oka, Takafumi Ueda, Sakae Tanaka

    Although initial trabectedin (1.2 mg/m2) is safe and effective for patients with translocation‐related sarcoma (TRS) in Japan, its efficacy in other types of soft‐tissue sarcomas (STSs) remains unknown. This study retrospectively investigated its efficacy and safety through postmarketing surveillance of trabectedin in patients with unresectable and relapsed STS.

    更新日期:2019-12-11
  • National treatment trends in human papillomavirus–positive oropharyngeal squamous cell carcinoma
    Cancer (IF 6.102) Pub Date : 2019-12-11
    Kevin Y. Zhan, Sidharth V. Puram, Michael M. Li, Dustin A. Silverman, Amit A. Agrawal, Enver Ozer, Matthew O. Old, Ricardo L. Carrau, James W. Rocco, Kevin M. Higgins, Danny J. Enepekides, Zain Husain, Stephen Y. Kang, Antoine Eskander

    Human papillomavirus (HPV)–mediated oropharyngeal cancer (OPC) is associated with dramatically improved survival in comparison with HPV‐negative OPC and can be successfully treated with surgical and nonsurgical approaches. National treatment trends for OPC were investigated with the National Cancer Data Base (NCDB).

    更新日期:2019-12-11
  • Communication during childhood cancer: Systematic review of patient perspectives
    Cancer (IF 6.102) Pub Date : 2019-12-10
    Beryl Lin, Talia Gutman, Camilla S. Hanson, Angela Ju, Karine Manera, Phyllis Butow, Richard J. Cohn, Luciano Dalla‐Pozza, Katie A. Greenzang, Jennifer Mack, Claire E. Wakefield, Jonathan C. Craig, Allison Tong

    Effective communication is challenging in childhood cancer, where decisions carry unpredictable and life‐threatening implications. We aimed to describe patients' experiences of communicating with clinicians during treatment of childhood cancer. A systematic review of qualitative studies to April 2019 was performed. Eligible studies included patients diagnosed with cancer at age ≤ 18 years and reported their perspectives of communicating with clinicians during treatment of childhood cancer. Data were extracted from primary studies for thematic synthesis. From 101 articles across 25 countries involving 1870 participants who were diagnosed with cancer between ages 3 to 18 years, we identified 6 themes: 1) rendered invisible and powerless (displaced and undermined by adult authority; betrayed and distrustful; feeling neglected; helpless and intimidated; disempowered by lack of information); 2) fear and worry for the future (paralyzed by devastating news; uncertainty, anticipation, and dread; broaching intimate and private topics); 3) burdened with responsibility (pressured and unprepared; balancing external expectations; protecting hope); 4) therapeutic patient-provider relationships (emotional support and encouragement; validated personhood and companionship); 5) safety in trust (truthfulness and transparency; prepared by awareness and understanding; reassured by reliable expertise; depending on adults for protection and difficult decisions; security in expressing opinions and needs); and 6) empowerment and assertive agency (right to individual knowledge and choice; control over own life; partnership and respect; enhancing capacity for self‐management). During treatment of childhood cancer, patients gain a sense of respect, safety, and control when they feel clinicians address their information and developmental needs. However, communication that is perceived to be parent‐centered can be disempowering. Promoting child agency and partnership may improve care and outcomes for children with cancer.

    更新日期:2019-12-11
  • Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer
    Cancer (IF 6.102) Pub Date : 2019-12-10
    Cornelius A. Thiels, Kristine T. Hanson, Elizabeth B. Habermann, Judy C. Boughey, Travis E. Grotz

    National Comprehensive Cancer Network (NCCN) guidelines recommend accurate clinical staging, perioperative therapy, and complete lymphadenectomy for patients with stage II to III gastric cancer. However, national compliance remains low. It was hypothesized that integrated cancer networks might improve compliance and outcomes within the community.

    更新日期:2019-12-11
  • ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small‐cell lung cancer cells to osimertinib
    Cancer (IF 6.102) Pub Date : 2019-12-10
    Yiting Li, Hongjing Zang, Guoqing Qian, Taofeek K. Owonikoko, Suresh R. Ramalingam, Shi‐Yong Sun

    Osimertinib (AZD9291), a third‐generation, mutation‐selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR‐TKI), is an approved drug for patients who have non–small‐cell lung cancer (NSCLC) with activating EGFR mutations or those harboring a resistant T790M mutation. Unfortunately, all patients eventually relapse and develop resistance to osimertinib. The current study addressed whether ERK inhibition exerts effects similar to those produced by MEK inhibition in overcoming acquired resistance to osimertinib.

    更新日期:2019-12-11
  • Wage losses among spouses of women with nonmetastatic breast cancer
    Cancer (IF 6.102) Pub Date : 2019-12-10
    Brittany Humphries, Sophie Lauzier, Mélanie Drolet, Douglas Coyle, Benoît Mâsse, Louise Provencher, André Robidoux, Elizabeth Maunsell

    The aim of this study was to evaluate the wage losses incurred by spouses of women with nonmetastatic breast cancer in the 6 months after the diagnosis.

    更新日期:2019-12-11
  • Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study
    Cancer (IF 6.102) Pub Date : 2019-12-10
    Jonathon B. Cohen, Lai Wei, Kami J. Maddocks, Beth Christian, Leonard T. Heffner, Amelia A. Langston, Mary Jo Lechowicz, Pierluigi Porcu, Christopher R. Flowers, Steven M. Devine, Kristie A. Blum

    Both gemcitabine and bendamustine have been evaluated in patients with recurrent/refractory Hodgkin lymphoma but to the authors' knowledge not as a doublet. The authors completed a phase 1/2 trial to identify the optimal dose and frequency of administration and to assess the efficacy of this combination in patients with recurrent/refractory Hodgkin lymphoma.

    更新日期:2019-12-11
  • Light to moderate amount of lifetime alcohol consumption and risk of cancer in Japan
    Cancer (IF 6.102) Pub Date : 2019-12-09
    Masayoshi Zaitsu, Takumi Takeuchi, Yasuki Kobayashi, Ichiro Kawachi

    Even light to moderate alcohol consumption has been shown to increase cancer incidence. However, this association has not been well characterized in Japan.

    更新日期:2019-12-09
  • Stroke impact on mortality and psychologic morbidity within the Childhood Cancer Survivor Study
    Cancer (IF 6.102) Pub Date : 2019-12-06
    Sabine Mueller, Cassie N. Kline, Robin A. Buerki, Yan Chen, Yutaka Yasui, Rebecca Howell, Kevin C. Oeffinger, Wendy M. Leisenring, Leslie L. Robison, Gregory T. Armstrong, Heather J. Fullerton, Kevin R. Krull

    Poor socioeconomic and health‐related quality of life (HRQOL) outcomes in survivors of childhood cancer can lead to distress and overall negatively impact the lives of these individuals. The current report has highlighted the impact of stroke and stroke recurrence on mortality, psychological HRQOL, and socioeconomic outcomes within the Childhood Cancer Survivor Study (CCSS).

    更新日期:2019-12-07
  • Patient‐hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study
    Cancer (IF 6.102) Pub Date : 2019-12-06
    Kah Poh Loh, Huiwen Xu, Anthony Back, Paul R. Duberstein, Supriya Gupta Mohile, Ronald Epstein, Colin McHugh, Heidi D. Klepin, Gregory Abel, Stephanie J. Lee, Areej El‐Jawahri, Thomas W. LeBlanc

    Ensuring that patients with hematologic malignancies have an accurate understanding of their likelihood of cure is important for informed decision making. In a multicenter, longitudinal study, the authors examined discordance in patients' perception of their chance of cure versus that of their hematologists, whether patient‐hematologist discordance changed after a consultation with a hematologist, and factors associated with persistent discordance.

    更新日期:2019-12-07
  • Trajectories of returning to work and its impact on survival in survivors with oral cancer: A 5‐year follow‐up study
    Cancer (IF 6.102) Pub Date : 2019-12-06
    Yuan‐Yuei Chen, Chung‐Ching Wang, Wei‐Te Wu, Ching‐Huang Lai, Ching‐Liang Ho, Ya‐Yuan Hsu, Wei‐Liang Chen

    A return to work (RTW) is a challenge for survivors of oral cancer. Further light could be shed on the RTW of patients with oral cancer, which remains largely uninvestigated. The objective of this study was to investigate the trajectories of RTW and their impact on survival in workers with oral cancer.

    更新日期:2019-12-07
  • Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer
    Cancer (IF 6.102) Pub Date : 2019-12-06
    Cristina Valero, Daniella K. Zanoni, Marlena R. McGill, Ian Ganly, Luc G.T. Morris, Miquel Quer, Jatin P. Shah, Richard J. Wong, Xavier León, Snehal G. Patel

    Inflammation and immune surveillance evasion are cancer hallmarks. Peripheral blood leukocytes (PBLs) represent both. The aim of the current study was to examine PBLs as predictors of outcomes in oral cavity squamous cell carcinoma (OSCC), and to find specific cutoffs with the goal of including PBLs as host factor in patients' preoperative risk assessment.

    更新日期:2019-12-07
  • Long‐term consequences of the USPSTF Grade D recommendation for prostate‐specific antigen screening
    Cancer (IF 6.102) Pub Date : 2019-12-03
    Shreyas S. Joshi, Christopher P. Filson

    The US Preventive Services Task Force Grade D recommendation for prostate cancer screening has had unintended consequences. Long‐term data now show a rise in advanced prostate cancer, especially for older men.

    更新日期:2019-12-04
  • Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate‐specific antigen screening in 2012
    Cancer (IF 6.102) Pub Date : 2019-12-03
    Santino S. Butler, Vinayak Muralidhar, Shuang G. Zhao, Nina N. Sanford, Idalid Franco, Zoe H. Fullerton, Janice Chavez, Anthony V. D’Amico, Felix Y. Feng, Timothy R. Rebbeck, Paul L. Nguyen, Brandon A. Mahal

    We sought to determine the extent to which US Preventive Services Task Force (USPSTF) 2012 Grade D recommendations against prostate‐specific antigen screening may have impacted recent prostate cancer disease incidence patterns in the United States across stage, National Comprehensive Cancer Network (NCCN) risk groups, and age groups.

    更新日期:2019-12-04
  • Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management
    Cancer (IF 6.102) Pub Date : 2019-12-03
    Caitlin R. Rausch, Elias J. Jabbour, Hagop M. Kantarjian, Tapan M. Kadia

    Optimal administration of the hyperCVAD regimen requires awareness of its appropriate administration and supportive care practices. Practical management of anticipated toxicities and treatment of special patient populations with this regimen is reviewed.

    更新日期:2019-12-04
Contents have been reproduced by permission of the publishers.
导出
全部期刊列表>>
限时免费阅读临床医学内容
ACS材料视界
科学报告最新纳米科学与技术研究
清华大学化学系段昊泓
自然科研论文编辑服务
中国科学院大学楚甲祥
中国科学院微生物研究所潘国辉
中国科学院化学研究所
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug